MRK vs SNY
Merck & Co. vs Sanofi — AI-powered side-by-side comparison
VS
SNY
Sanofi
62
Insufficient Data
| Metric | MRK | SNY |
|---|
| AI Score |
70
|
62
|
| Price |
$130.34
|
$43.56
|
| P/E Ratio |
103.53×
|
23.06×
|
| ROE |
34.7%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
72.8%
|
| Debt / Equity |
1.29×
|
0.34×
|
| Dividend Yield |
2.6%
|
5.5%
|
| RSI (14) |
64.5
|
53.1
|
| Beta |
0.207
|
0.278
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for MRK versus SNY.
MRK leads by 8 points.
MRK scores 70/100 (Buy) versus SNY at 62/100 (Insufficient Data).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical